Actively Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Led by Jacobio Pharmaceuticals Co., Ltd. · Updated on 2026-01-09
102
Participants Needed
8
Research Sites
240 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
CONDITIONS
Official Title
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Must be able to provide an archived tumor sample
-
Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
- Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated
-
Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition
-
Must have at least 1 measurable lesion per RECIST v1.1
-
Must have adequate organ functions
-
Must be able to swallow and retain orally administered medication
You will not qualify if you...
- Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days
- Active infection requiring systemic treatment within 7 days
- Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV
- Any severe and/or uncontrolled medical conditions
- left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
- QT interval using Fridericia's formula (QTcF) interval >470 msec
- Experiencing unresolved CTCAE 5.0 Grade >1 toxicities
- Clinically significant eye disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
2
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
3
Mary Crowley Cancer Research
Dallas, Texas, United States, 75230
Actively Recruiting
4
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
5
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100101
Actively Recruiting
6
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100101
Actively Recruiting
7
Jilin Cancer Hospital
Changchun, Jilin, China, 130000
Actively Recruiting
8
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
J
Jacobio Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here